Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients

Annals of Neurology

Volumn 44, Issue 5, 1998, Pages 819-824

  Pedersen, Ward A ^a,b   Fu, Weiming ^a   Keller, Jeffrey N ^a   Markesbery, William R ^a   Appel, Stanley ^c   Smith, R Glenn ^c   Kasarskis, Edward ^a   Mattson, Mark P ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CELL DAMAGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LIPID PEROXIDATION; MEMBRANE TRANSPORT; PRIORITY JOURNAL; PROTEIN MODIFICATION; SPINAL CORD; SPINAL CORD VENTRAL HORN; SYNAPTOSOME;

EID: 0031768026     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410440518     Document Type: Article

References (24)

1. Mitsumoto H. Diagnosis and progression of ALS. Neurology 1997;48(Suppl 4):2-8
2. Cudkowicz ME, McKenna-Yasek D, Sapp PE, et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol 1997;41:210-221
3. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994;264:1772-1775
4. Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147-157
5. Yim MB, Kang JH, Yim HS, et al. A gain-of-function of an amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutant: an enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. Proc Nad Acad Sci USA 1996;93:5709-5714
6. Bruijn LI, Beal MF, Becher MW, et al. Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. Proc Natl Acad Sci USA 1997;94:7606-7611
7. Ferrante RJ, Browne SE, Shinobu LA, et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997;69:2064-2074
8. Spencer PS, Nunn PB, Hugon J, et al. Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. Science 1987;237:517-522
9. Rothstein JD, Tsai G, Kuncl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990;28:18-25
10. Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. New Engl J Med 1992;326:1464-1468
11. Canton T, Pratt J, Stutzmann JM, et al. Glutamate uptake is decreased tardively in the spinal cord of FALS mice. Neuroreport 1998;9:775-778
12. Rothstein JD, VanKammen BA, Levey AI, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84
13. Rothstein JD, Dykes-Hoberg M, Pardo CA, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996; 16:675-686
14. Bensimon G, Lacomblez L, Meininger V. The ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591
15. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991;11:81-128
16. Waeg G, Dimsity G, Esterbauer H. Monoclonal antibodies for detection of 4-hydroxynonenal modified proteins. Free Radic Res 1996;25:149-159
17. Oda Y, Imai S, Nakanishi I, et al. Immunohistochemical study on choline acetyltransferase in the spinal cord of patients with amyotrophic lateral sclerosis. Pathol Int 1995;45:933-939
18. Lovell MA, Ehmann WD, Mattson MP, et al. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 1997;18:457-461
19. Mark RJ, Lovell MA, Markesbery WR, et al. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid β-peptide. J Neurochem 1997;68:255-264
20. Keller JN, Pang Z, Geddes JW, et al. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid-β peptide: role of the lipid peroxidation product 4-hydroxynonenal. J Neurochem 1997;69:273-284
21. Keller JN, Mark RJ, Bruce AJ, et al. 4-Hydroxynonenal, an aldehydic product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in synaptosomes. Neuroscience 1997;80:685-696
22. Blanc EM, Keller JN, Fernandez S, et al. 4-Hydroxynonenal, a lipid peroxidation product, inhibits glutamate transport in astrocytes. Glia 1998;22:149-160
23. Kostic V, Jackson-Lewis V, de Bilbao F, et al. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 1997;277:559-562
24. Bruce-Keller AJ, Begley JG, Fu W, et al. Bcl-2 protects isolated plasma and mitochondrial membranes against lipid peroxidation induced by hydrogen peroxide and amyloid β-peptide. J Neurochem 1997;70:31-39